352 related articles for article (PubMed ID: 26989027)
41. Targeted next generation sequencing in Chinese colorectal cancer patients guided anti-EGFR treatment and facilitated precision cancer medicine.
Hou H; Liu D; Zhang C; Jiang Y; Lu G; Zhou N; Yang X; Zhang X; Li Z; Zhu H; Qian Z; Zhang X
Oncotarget; 2017 Dec; 8(62):105072-105080. PubMed ID: 29285234
[TBL] [Abstract][Full Text] [Related]
42. Detection of genes responsible for cetuximab sensitization in colorectal cancer cells using CRISPR-Cas9.
Hu TT; Yang JW; Yan Y; Chen YY; Xue HB; Xiang YQ; Ye LC
Biosci Rep; 2020 Oct; 40(10):. PubMed ID: 33048115
[TBL] [Abstract][Full Text] [Related]
43. Oncogenic composite mutations can be predicted by co-mutations and their chromosomal location.
Küçükosmanoglu A; van der Borden CL; de Boer LEA; Verhaak R; Noske D; Wurdinger T; Radonic T; Westerman BA
Mol Oncol; 2024 May; ():. PubMed ID: 38757376
[TBL] [Abstract][Full Text] [Related]
44. Colorectal cancer in Chinese patients: current and emerging treatment options.
Li L; Ma BB
Onco Targets Ther; 2014; 7():1817-28. PubMed ID: 25336973
[TBL] [Abstract][Full Text] [Related]
45. KRAS, NRAS and BRAF mutations in colorectal cancer and melanoma.
Cicenas J; Tamosaitis L; Kvederaviciute K; Tarvydas R; Staniute G; Kalyan K; Meskinyte-Kausiliene E; Stankevicius V; Valius M
Med Oncol; 2017 Feb; 34(2):26. PubMed ID: 28074351
[TBL] [Abstract][Full Text] [Related]
46. RAS mutation is a prognostic biomarker in colorectal cancer patients with metastasectomy.
Osumi H; Shinozaki E; Suenaga M; Matsusaka S; Konishi T; Akiyoshi T; Fujimoto Y; Nagayama S; Fukunaga Y; Ueno M; Mise Y; Ishizawa T; Inoue Y; Takahashi Y; Saiura A; Uehara H; Mun M; Okumura S; Mizunuma N; Miki Y; Yamaguchi T
Int J Cancer; 2016 Aug; 139(4):803-11. PubMed ID: 27004837
[TBL] [Abstract][Full Text] [Related]
47. Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX.
Ciardiello F; Normanno N; Martinelli E; Troiani T; Pisconti S; Cardone C; Nappi A; Bordonaro AR; Rachiglio M; Lambiase M; Latiano TP; Modoni G; Cordio S; Giuliani F; Biglietto M; Montesarchio V; Barone C; Tonini G; Cinieri S; Febbraro A; Rizzi D; De Vita F; Orditura M; Colucci G; Maiello E;
Ann Oncol; 2016 Jun; 27(6):1055-1061. PubMed ID: 27002107
[TBL] [Abstract][Full Text] [Related]
48. BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis.
Nam SK; Yun S; Koh J; Kwak Y; Seo AN; Park KU; Kim DW; Kang SB; Kim WH; Lee HS
PLoS One; 2016; 11(3):e0151865. PubMed ID: 26991109
[TBL] [Abstract][Full Text] [Related]
49. Prognostic impact of mutation profiling in patients with stage II and III colon cancer.
Shen Y; Han X; Wang J; Wang S; Yang H; Lu SH; Shi Y
Sci Rep; 2016 Apr; 6():24310. PubMed ID: 27074743
[TBL] [Abstract][Full Text] [Related]
50. The Best. First. Anti-EGFR before anti-VEGF, in the first-line treatment of RAS wild-type metastatic colorectal cancer: from bench to bedside.
Zaniboni A; Formica V
Cancer Chemother Pharmacol; 2016 Aug; 78(2):233-44. PubMed ID: 27091467
[TBL] [Abstract][Full Text] [Related]
51. Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases.
Løes IM; Immervoll H; Sorbye H; Angelsen JH; Horn A; Knappskog S; Lønning PE
Int J Cancer; 2016 Aug; 139(3):647-56. PubMed ID: 26991344
[TBL] [Abstract][Full Text] [Related]
52. ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours.
Segelov E; Waring P; Desai J; Wilson K; Gebski V; Thavaneswaran S; Elez E; Underhill C; Pavlakis N; Chantrill L; Nott L; Jefford M; Khasraw M; Day F; Wasan H; Ciardiello F; Karapetis C; Joubert W; van Hazel G; Haydon A; Price T; Tejpar S; Tebbutt N; Shapiro J
BMC Cancer; 2016 May; 16():339. PubMed ID: 27246726
[TBL] [Abstract][Full Text] [Related]
53. First-Line Cetuximab Monotherapy in KRAS/NRAS/BRAF Mutation-Negative Colorectal Cancer Patients.
Moiseyenko VM; Moiseyenko FV; Yanus GA; Kuligina ES; Sokolenko AP; Bizin IV; Kudriavtsev AA; Aleksakhina SN; Volkov NM; Chubenko VA; Kozyreva KS; Kramchaninov MM; Zhuravlev AS; Shelekhova KV; Pashkov DV; Ivantsov AO; Venina AR; Sokolova TN; Preobrazhenskaya EV; Mitiushkina NV; Togo AV; Iyevleva AG; Imyanitov EN
Clin Drug Investig; 2018 Jun; 38(6):553-562. PubMed ID: 29470838
[TBL] [Abstract][Full Text] [Related]
54. KDR Mutation as a Novel Predictive Biomarker of Exceptional Response to Regorafenib in Metastatic Colorectal Cancer.
Loaiza-Bonilla A; Jensen CE; Shroff S; Furth E; Bonilla-Reyes PA; Deik AF; Morrissette J
Cureus; 2016 Feb; 8(2):e478. PubMed ID: 27004155
[TBL] [Abstract][Full Text] [Related]
55. Reconsidering the benefit of intermittent versus continuous treatment in the maintenance treatment setting of metastatic colorectal cancer.
Sunakawa Y; Bekaii-Saab T; Stintzing S
Cancer Treat Rev; 2016 Apr; 45():97-104. PubMed ID: 27002945
[TBL] [Abstract][Full Text] [Related]
56. Cetuximab as First-line Treatment for Metastatic Colorectal Cancer: Caution With Interpretation of Cost-Effectiveness Results Toward Medical Decision Making.
Franken MD; Koopman M; van Oijen MG
Am J Clin Oncol; 2016 Apr; 39(2):214. PubMed ID: 26999056
[No Abstract] [Full Text] [Related]
57. Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2.
Foster SA; Whalen DM; Özen A; Wongchenko MJ; Yin J; Yen I; Schaefer G; Mayfield JD; Chmielecki J; Stephens PJ; Albacker LA; Yan Y; Song K; Hatzivassiliou G; Eigenbrot C; Yu C; Shaw AS; Manning G; Skelton NJ; Hymowitz SG; Malek S
Cancer Cell; 2016 Apr; 29(4):477-493. PubMed ID: 26996308
[TBL] [Abstract][Full Text] [Related]
58. Efficacy of cetuximab-based chemotherapy in metastatic colorectal cancer according to RAS and BRAF mutation subgroups: A meta-analysis.
Lin LI; Chen LL; Wang Y; Meng XY; Liang C; Zhou FX
Mol Clin Oncol; 2016 Jun; 4(6):1017-1024. PubMed ID: 27284437
[TBL] [Abstract][Full Text] [Related]
59. Mutation profiling in chinese patients with metastatic colorectal cancer and its correlation with clinicopathological features and anti-EGFR treatment response.
Li ZZ; Wang F; Zhang ZC; Wang F; Zhao Q; Zhang DS; Wang FH; Wang ZQ; Luo HY; He MM; Wang DS; Jin Y; Ren C; Qiu MZ; Ren J; Pan ZZ; Li YH; Shao JY; Xu RH
Oncotarget; 2016 May; 7(19):28356-68. PubMed ID: 27050078
[TBL] [Abstract][Full Text] [Related]
60. Review on EGFR Inhibitors: Critical Updates.
Singh D; Attri BK; Gill RK; Bariwal J
Mini Rev Med Chem; 2016; 16(14):1134-66. PubMed ID: 26996617
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
